Genomic Characterization of Endothelial Barrier Disruption During Severe Systemic Inflammation

Abstract

Severe systemic inflammation, including sepsis, septic shock, acute respiratory distress syndrome, and hyperinflammatory syndromes, is characterized by profound disruption of the endothelial barrier. Endothelial injury increases vascular permeability, promotes tissue edema, impairs microcirculatory flow, and contributes to multiorgan dysfunction. Genomic technologies have expanded understanding of this process by identifying transcriptional programs involving inflammatory signaling, junctional integrity, glycocalyx maintenance, coagulation, leukocyte adhesion, oxidative stress, and endothelial cell death. Single-cell RNA sequencing, spatial transcriptomics, epigenomic profiling, and circulating nucleic acid analysis have revealed substantial endothelial heterogeneity across vascular beds and disease stages. These findings support a model in which endothelial dysfunction is not a uniform consequence of inflammation but a dynamically regulated and organ-specific process. Clinically, genomic characterization may improve risk stratification, identify biologically defined patient subgroups, and guide development of targeted therapies. Current management remains centered on rapid treatment of the underlying inflammatory trigger, appropriate antimicrobial therapy when infection is suspected, hemodynamic stabilization, lung-protective ventilation, and prevention of secondary organ injury. Emerging approaches include endothelial-directed therapies, modulation of angiopoietin and Tie2 signaling, complement inhibition, glycocalyx preservation, and precision immunomodulation. Translation into routine practice will require validated biomarkers, standardized sampling, prospective clinical trials, and careful integration of molecular information with bedside assessment.

Introduction

The vascular endothelium is an active organ that regulates permeability, vascular tone, leukocyte trafficking, coagulation, platelet interactions, and tissue repair. During severe systemic inflammation, endothelial cells respond to pathogen-associated molecular patterns, damage-associated molecular patterns, cytokines, complement activation, thrombin, reactive oxygen species, and mechanical stress. The resulting loss of barrier function permits plasma proteins and fluid to leave the intravascular space, while endothelial activation facilitates leukocyte adhesion and microvascular thrombosis. These changes are central to the development of hypotension, pulmonary edema, acute kidney injury, encephalopathy, myocardial dysfunction, and other manifestations of critical illness.

Traditional investigations have described endothelial injury through circulating proteins, vascular permeability measurements, histopathology, and physiological endpoints. Genomic characterization adds a higher-resolution view by examining how endothelial cells alter gene expression and chromatin accessibility during inflammation. This approach is particularly important because endothelial responses differ according to vascular bed, developmental origin, exposure to local mediators, and disease phase. Understanding these molecular differences may allow clinicians and researchers to distinguish reversible endothelial activation from progressive structural injury and to identify patients most likely to benefit from targeted treatment.

Epidemiology / Disease Burden

Endothelial barrier disruption is common in patients with sepsis and other forms of critical illness, although its prevalence is not captured by a single diagnostic test. Sepsis remains a major cause of death and disability worldwide, with a substantial burden resulting from shock and multiple-organ dysfunction rather than the primary infection alone. Acute respiratory distress syndrome, frequently associated with systemic inflammation, is defined by increased pulmonary vascular permeability and carries considerable mortality, particularly when accompanied by extrapulmonary organ failure. Similar endothelial mechanisms occur in severe viral infections, pancreatitis, major trauma, burns, autoimmune flares, and extracorporeal circulation.

The clinical burden extends beyond acute mortality. Survivors may experience persistent weakness, cognitive impairment, renal dysfunction, impaired exercise tolerance, and recurrent hospitalization. Molecular studies indicate that endothelial transcriptional alterations can persist after the initial inflammatory insult, potentially contributing to prolonged microvascular dysfunction and delayed recovery. Disease burden is also influenced by age, comorbidity, biological sex, genetic background, pathogen characteristics, and the timing of treatment. These factors reinforce the need for molecular phenotyping that can complement conventional severity scores.

Pathophysiology

Genomic studies identify several interconnected pathways in endothelial barrier failure. Nuclear factor kappa B, activator protein 1, interferon-regulated transcription factors, and signal transducer and activator of transcription proteins coordinate expression of cytokines, chemokines, adhesion molecules, and acute inflammatory mediators. Upregulation of E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 promotes leukocyte rolling, adhesion, and transmigration. At the same time, inflammatory signaling can suppress genes involved in endothelial quiescence and vascular stability.

Disruption of adherens and tight junctions is a major molecular event. Altered expression or phosphorylation of vascular endothelial cadherin, claudins, occludin, and zonula occludens proteins weakens cell-cell contacts. Cytoskeletal contraction, driven by Rho kinase, myosin light-chain activation, calcium signaling, and thrombin receptors, produces intercellular gaps. The endothelial glycocalyx is also degraded by heparanase, metalloproteinases, reactive oxygen species, and inflammatory proteases. Loss of glycocalyx components increases permeability and exposes adhesion and coagulation surfaces.

Single-cell analyses demonstrate that endothelial cells from the lung, kidney, heart, and brain express distinct inflammatory and repair programs. Some populations show interferon responses and antigen-presentation signatures, whereas others display angiogenic, hypoxic, or prothrombotic profiles. Endothelial-to-mesenchymal transition-like programs may further impair barrier function and tissue repair. Mitochondrial stress, impaired nitric oxide signaling, altered fatty-acid metabolism, pyroptosis, apoptosis, and regulated necrotic pathways can amplify vascular injury. These genomic observations support a model in which barrier failure results from the interaction of inflammatory transcription, metabolic stress, and tissue-specific microenvironmental signals.

Risk Factors

Risk factors for severe endothelial dysfunction include advanced age, diabetes mellitus, obesity, chronic kidney disease, cardiovascular disease, chronic lung disease, malignancy, immunosuppression, and pre-existing vascular inflammation. Severe or delayed-treated infection, high pathogen burden, persistent bacteremia, prolonged hypotension, and uncontrolled tissue injury increase exposure to endothelial-damaging mediators. Mechanical ventilation with excessive airway pressures, transfusion-related inflammation, extracorporeal support, and nephrotoxic or vasoconstrictive therapies may intensify microvascular stress. Genetic variation in innate immune, complement, coagulation, and endothelial signaling pathways may also influence susceptibility, although most findings require further clinical validation.

Clinical Features

Clinical manifestations reflect the distribution and severity of barrier failure. Pulmonary involvement produces hypoxemia, diffuse infiltrates, reduced lung compliance, and increased ventilatory support requirements. Systemic leakage can cause edema, intravascular volume depletion, hypotension, rising lactate, and impaired response to vasopressors. Kidney involvement may present with oliguria, increasing creatinine, and tubular injury. Cerebral endothelial dysfunction can contribute to delirium and encephalopathy, while myocardial microvascular injury may produce reduced contractility or arrhythmia. Skin mottling, prolonged capillary refill, cool extremities, and peripheral cyanosis indicate impaired microcirculatory perfusion but are not specific for a single molecular mechanism.

Diagnosis

Diagnosis remains clinical and requires integration of history, examination, laboratory testing, imaging, and continuous physiological monitoring. Standard evaluation includes assessment of oxygenation, blood pressure, urine output, lactate, renal and hepatic function, coagulation, blood counts, and microbiological results. Biomarkers such as angiopoietin-2, soluble thrombomodulin, syndecan-1, soluble adhesion molecules, and cell-free DNA may reflect endothelial activation or injury, but thresholds and clinical utility are not yet sufficiently standardized for routine decision-making.

Genomic testing is currently most useful in research and specialized translational settings. Bulk RNA sequencing of tissue or circulating cells can identify inflammatory pathways, while single-cell RNA sequencing resolves cellular subpopulations and disease-associated states. Spatial transcriptomics can map endothelial programs to specific anatomical regions, and chromatin accessibility studies reveal regulatory changes that may persist after inflammatory signals decline. Circulating endothelial-cell RNA, extracellular vesicles, and cell-free nucleic acids are promising minimally invasive sources, but preanalytical variation, low abundance, tissue contamination, and differences in sequencing pipelines remain substantial limitations.

Treatment & Management

Management should prioritize rapid treatment of the precipitating condition. When infection is suspected, timely microbiological evaluation and appropriate antimicrobial therapy are essential, with subsequent de-escalation guided by clinical response and available results. Hemodynamic support should use balanced crystalloid fluids when indicated, frequent reassessment of fluid responsiveness, and vasopressors for persistent hypotension. Excessive fluid administration should be avoided because worsening interstitial edema can further impair oxygen diffusion and organ function. Norepinephrine is generally preferred for septic vasodilatory shock, while additional agents may be considered in selected patients.

Organ support should be protective and individualized. Lung-protective ventilation, appropriate positive end-expiratory pressure, prone positioning in suitable patients with severe hypoxemia, renal replacement therapy when indicated, venous thromboembolism prevention, nutritional support, glycemic management, and early mobilization are important components of care. There is no approved genomic therapy that directly reverses endothelial barrier disruption. Investigational strategies include Tie2 pathway activation, angiopoietin modulation, glycocalyx preservation, complement inhibition, antioxidant approaches, and selective blockade of inflammatory or coagulation signaling. Such therapies must be balanced against the risks of immunosuppression, bleeding, thrombosis, and impaired host defense.

Recent Advances / Emerging Therapies

Recent advances have emphasized endothelial heterogeneity and disease endotypes rather than a single universal inflammatory signature. Single-cell and spatial methods are identifying endothelial states associated with permeability, tissue-specific inflammation, repair, and thrombosis. Multi-omic integration may permit simultaneous analysis of transcription, chromatin regulation, protein expression, and metabolic activity. Machine-learning models are being developed to combine these data with clinical variables, but external validation and transparent reporting are necessary before implementation.

Potential therapeutic directions include restoration of Tie2 signaling, inhibition of angiopoietin-2 activity, stabilization of vascular endothelial cadherin, reduction of glycocalyx degradation, and targeted control of complement-mediated injury. Nanoparticle delivery and cell-selective drug targeting may eventually allow treatment of activated endothelial populations while limiting systemic toxicity. Precision approaches could also identify patients with predominant endothelial inflammation, thromboinflammation, or metabolic dysfunction. However, the timing of intervention is critical: a pathway that is harmful during acute barrier failure may participate in later repair. Clinical trials should therefore incorporate biological selection, longitudinal sampling, and organ-specific outcomes.

Guideline Recommendations

Current international guidance supports early recognition and treatment of sepsis, prompt source control, appropriate antimicrobial administration, individualized fluid resuscitation, vasopressor support for persistent shock, and regular reassessment of perfusion. Recommendations also emphasize avoidance of unnecessary fluid accumulation, lung-protective ventilation in acute respiratory distress syndrome, venous thromboembolism prophylaxis when safe, and daily evaluation of organ support. No major guideline currently recommends routine genomic profiling of endothelial function because assays lack harmonized platforms, validated reference ranges, and proven effects on patient outcomes.

Clinicians should interpret emerging endothelial biomarkers as adjunctive research or specialized clinical information rather than replacements for bedside assessment. Genomic results should not delay antimicrobials, source control, hemodynamic stabilization, or organ support. Future recommendations will require prospective trials demonstrating that molecular classification improves treatment selection, reduces adverse events, or improves survival and quality of life.

Conclusion

Genomic characterization has clarified that endothelial barrier disruption during severe systemic inflammation is a complex, heterogeneous, and temporally evolving process. Alterations in inflammatory transcription, junctional proteins, glycocalyx regulation, coagulation, metabolism, and cell survival collectively produce vascular leak and microvascular dysfunction. Single-cell, spatial, and multi-omic technologies are beginning to define clinically meaningful endothelial states, but routine genomic testing remains premature. Current care should continue to focus on rapid treatment of the underlying cause, careful hemodynamic management, protective organ support, and prevention of secondary injury. The next phase of research should connect validated molecular signatures with treatment response and patient-centered outcomes, enabling safe precision medicine for inflammatory vascular injury.